Estimating Minimally Important Differences for the Worst Pain Rating of the Brief Pain Inventory–Short Form
April 2, 2011|The Journal of Community and Supportive Oncology
Author and Disclosure Information
The Brief Pain Inventory–Short Form (BPI-SF) is widely used for assessing pain in clinical and research studies. The worst pain rating is often the primary outcome of interest; yet, no published data are available on its minimally important difference (MID). Breast cancer patients with bone metastases enrolled in a randomized, double-blind, phase III study comparing denosumab with zoledronic acid for preventing skeletal related events and completed the BPI-SF, FACT-B, and EQ-5D at baseline, week 5, and monthly through the end of the study. Anchor- and distribution-based
Conflicts of interest: This research was funded by Amgen Inc., Thousand Oaks, CA in part through a contract to Health Outcomes Solutions. SDM and RDC were paid by Health Outcomes Solutions, and YQ, QJ, RD and KC are employees of Amgen and own Amgen stock and stock options.
Correspondence to: Susan D. Mathias, Health Outcomes Solutions, PO Box 2343, Winter Park, FL 32790; telephone: (407) 643-9016; fax: (866) 384-0194
